Navigation Links
Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product
Date:12/11/2008

Exclusive prescription spray product to treat Xerostomia will compete in $1 Billion US Market

RED BANK, N.J., Dec. 11 /PRNewswire/ -- Bi-Coastal Pharmaceutical Corp. announced today that it has acquired the US marketing rights to Aquoral(TM) artificial saliva. Aquoral(TM) is a lipid based artificial saliva spray product that is currently the only Prescription spray product marketed in the United States to treat Xerostomia. The total US market for products treating Xerostomia was estimated at $1 Billion in 2007. The product is sold in a 40ml (1.4 fl. oz.) spray bottle that if used as directed is a 2 month supply. Aquoral(TM) has already received overwhelming acceptance by physicians as well as patients suffering with Xerostomia. The sales and marketing of Aquoral(TM) will begin by Bi-Coastal to the Pharmaceutical trade channels immediately.

Bi-Coastal Pharmaceutical Corp. is a leading Sales, Marketing and Consulting company founded in 1982 and based in Red Bank, New Jersey. Since 2001, Bi-Coastal has secured product sales in excess of $650 Million. Bi-Coastal is currently finalizing its multi-faceted sales and marketing plans for Aquoral(TM) that will include an aggressive trade and physician advertising campaign, telemarketing, direct mail and other programs to physicians as well as a detail sales force initially targeting the Dental, Oncology, Rheumatology and Managed Care markets.

Ralph Massa, Jr., Bi-Coastal Pharmaceutical Corp.'s President and Chief Operating Officer stated the following, "I am pleased to announce the acquisition of Aquoral(TM) and confident that we will achieve significant sales levels well within the first year of marketing the product. Aquoral(TM) will soon be a trusted and proven household name to treat Xerostomia as it is an extremely effective and easy to use product with no known adverse effects. We look forward to the official re-launch of Aquoral(TM) to the trade at the upcoming ECRM conference in Destin, Florida next month as well as discussing many other products that will be a part of Bi-Coastal's exciting product portfolio in 2009."

    For more information please contact:

    Ralph Massa, Jr.
    President and Chief Operating Officer
    Bi-Coastal Pharmaceutical Corp.
    130 Maple Avenue
    Red Bank, New Jersey 07701
    www.bicoastalpharm.com
    Tel-(732) 530-6606 Ext 132
    Fax-(732) 530-1521
    e-mail: rmassa@bicoastalpharm.com


'/>"/>
SOURCE Bi-Coastal Pharmaceutical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaDetail, Inc. Continues Bi-coastal Expansion
2. Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities
3. Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
4. Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt
5. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. Pharmaceutical Water Markets, the Economic Crunch Creates New Opportunities in Southern and Eastern Europe
11. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
Breaking Medicine Technology: